Peptide Injections: What They Are, Routes, Cost and Results

Chemically, insulin, semaglutide and BPC-157 all count as peptides. Regulatorily they sit in different worlds, and the label (or its absence) is the dividing line.

A few compounds sit awkwardly between categories. Sermorelin was an FDA-approved drug (Geref, EMD Serono, approved 1997) that is now discontinued; FDA's record notes it was not withdrawn for safety or effectiveness reasons. PT-141 is the research name for bremelanotide, which is approved as Vyleesi for one specific indication. Each compound's dosage page on this site says which category it is in, for example semaglutide, tesamorelin, sermorelin and BPC-157.

Nearly every peptide shot people ask about is subcutaneous (SC): injected into the fat layer between skin and muscle. The approved labels are consistent on this. Ozempic is injected subcutaneously in the abdomen, thigh or upper arm, and its Medication Guide says not to inject it into a muscle or vein. Egrifta SV is injected subcutaneously into the abdomen. Vyleesi is given subcutaneously into the abdomen or thigh by autoinjector.

Intramuscular (IM) injection is the exception. Miacalcin (calcitonin salmon) is one of the few peptide labels that allows either route, and it states that if the volume exceeds 2 mL, intramuscular injection is preferable and the dose should be split across several sites. The diabetes injection-technique consensus known as FITTER goes the other way for insulin: it recommends the shortest needles and says intramuscular injection should be avoided, especially with long-acting insulins, because severe hypoglycemia may result.

Where exactly to place a subcutaneous shot, how to rotate, and what needle length and angle the labels describe are covered in detail in peptide injection sites.

The physical process depends on the presentation, and there are three common ones.

Pre-filled pen

Brand GLP-1 drugs mostly come as multi-dose pens. The Ozempic pen ships with NovoFine Plus 32G 4 mm needles; you attach a new needle each time, dial the dose, inject, and remove the needle afterwards. The label is explicit that a pen must never be shared between patients, even if the needle is changed.

Single-dose autoinjector or pre-filled syringe

Vyleesi is a single-dose autoinjector: press it against the abdomen or front of the thigh and it delivers a fixed dose. Ozempic is now also available as single-dose pre-filled syringes, which the instructions say to insert into a pinched fold of skin at a 45-degree angle.

Vial and syringe (reconstitution)

Freeze-dried peptides arrive as powder that must be dissolved first. Egrifta SV is the approved example: each 2 mg vial is mixed with the supplied Sterile Water for Injection using a 1 mL syringe and a mixing needle, then injected with a separate ½-inch 30-gauge needle. Research-market vials follow the same pattern but with no instructions you can rely on; the steps are in the reconstitution guide.

Whatever the device, the instructions across these labels repeat the same basics: a new needle every time, clean and dry skin, rotate the site, never through clothing, and used needles into a sharps container.

A pen hides the arithmetic: you dial a milligram dose and the pen meters it. A vial does not. You have to turn a dose in milligrams (or micrograms) into a volume, and on a U-100 insulin syringe that volume is read in units, where 1 unit = 0.01 mL.

The formula: units = dose (mg) ÷ (vial mg ÷ mL of water added) × 100.

The concentration above is an illustration only, not a recommended preparation. Change the water volume and every row changes, which is why the same dose can be 10 units for one person and 25 for another. Run your own numbers in the mg to mL to units converter, and see the syringe measurement guide for reading the barrel. Compounded or research vials are not equivalent to branded pens even at the same milligram figure: the label's dose was established with the approved product, and a vial's labelled mass is the seller's claim.

Before-and-after photos are the most common way peptide shots are sold, and the least informative. A photo has no control group, no standardised lighting or posture, and no way to separate the injection from diet, training, time or a different drug. Controlled trials are the only results that mean anything, and they only exist for the approved products. Their labels report them plainly, and the effects are real but bounded.

Two points follow. First, even approved peptides produce averages with wide individual variation, and the Egrifta label tells prescribers to weigh continuing treatment in patients who have not had a reduction. Second, for research compounds, testimonials and photos are not a weaker version of evidence; they are a different thing altogether. For the GLP-1 drugs, where trial data are extensive, see the brand pages: Ozempic dosage chart and Mounjaro dosage chart.

Prices vary too widely by product, pharmacy, insurer and country to quote responsibly, and they change often. What can be stated is which factors move the number and in which direction.

A low price is not neutral information. With a research vial, the cheapest option is often the one with the least testing behind the labelled milligram figure.

Searches for peptide injections near me usually lead to three kinds of source, with very different legal footing.

1. A prescriber and a licensed pharmacy. For approved peptides this is the only route that gets you the product the label describes. Telehealth services are prescribers too; the drug still comes from a pharmacy.
2. Compounding pharmacies. Pharmacies working under section 503A compound on a prescription for a named patient; 503B outsourcing facilities register with FDA and meet higher quality standards. FDA is clear that compounded drugs are not FDA-approved.
3. Peptide or wellness clinics selling research compounds. FDA keeps a public list of bulk substances that may present significant safety risks in compounding. As of April 2026 it includes ipamorelin, GHRP-2, GHRP-6, kisspeptin-10 and ibutamoren (MK-677), citing risks such as immunogenicity and, for ibutamoren, a congestive heart failure signal. BPC-157, CJC-1295, AOD-9604, TB-500 and injectable GHK-Cu were nominated, flagged for similar concerns, then withdrawn by the nominators.

Questions worth asking any clinic: Is this an FDA-approved product or compounded? Which pharmacy makes it, and is it 503A or 503B? What dose, and where does that number come from? What happens if I get a reaction? A clinic that cannot answer the second and third questions is telling you something.

This page is the overview. The detail lives on dedicated pages:

• Weight management: the GLP-1 and dual-agonist drugs have their own guide, weight loss injections, which links on to each brand's dosing page.
• Skin: copper peptide (GHK-Cu) and "collagen" injections, and why most of the skin evidence is topical: peptide injections for skin.
• Growth-hormone axis: tesamorelin (approved), sermorelin (formerly approved), and research secretagogues such as CJC-1295 and ipamorelin.
• Sexual function: PT-141 (bremelanotide).
• Repair claims: BPC-157 and TB-500, both without approved human use.

The approved labels agree on a short list of practical rules, and they apply equally to anything injected from a vial:

• Never share a pen, syringe or needle, even with a new needle: the Ozempic label warns of blood-borne pathogen transmission, and the Egrifta SV label of infection.
• New needle, every injection, and dispose of it in a sharps container.
• Rotate sites to reduce injection-site reactions and skin changes.
• Expect some site reactions. They are common even with approved products: injection-site reactions were reported in 25% of Egrifta patients vs 14% on placebo, and 13.2% on Vyleesi vs 8.4% on placebo.
• Stay within the label. For prescription peptides, dose changes belong to the prescriber, and no dose above a label maximum is supported by the evidence behind it.